SLP Simulations Plus

Simulations Plus Announces Fourth Quarter and Fiscal Year 2024 Earnings and Conference Call Date

LANCASTER, Calif.--(BUSINESS WIRE)--

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024.

Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering . The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this link to request a return call. The webcast can be accessed on the investor relations page of the Simulations Plus website at where it will also be available for replay approximately one hour following the call.

About Simulations Plus, Inc.

With more than 25 years of experience serving clients globally, Simulations Plus stands as a premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization. Our comprehensive biosimulation solutions integrate artificial intelligence/machine learning (AI/ML), physiologically based pharmacokinetics, physiologically based biopharmaceutics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. We also deliver simulation-enabled performance and intelligence solutions alongside medical communications support for clinical and commercial drug development. Our cutting-edge technology is licensed and utilized by leading pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at . Follow us on | | .

Environmental, Social, and Governance (ESG)

We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our

EN
09/10/2024

Underlying

SLPSimulations Plus

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Simulations Plus

 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus to Participate in the BTIG Digital Health Forum

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in the virtual BTIG Digital Health Forum on Monday, November 25, 2024. Mr. O’Connor will join a panel discussion entitled “Supporting Drug Development, Clinical Trials, and Biopharma” at 2:00 p.m. Eastern Time. In addition, Mr. O’Connor will host one-on-one meetings through...

November 19, 2024 1 EN
 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus and the University of Connecticut Receive New FDA Gra...

LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it has been awarded a newly funded grant from the U.S. Food and Drug Administration (FDA) to use physiologically based pharmacokinetic (PBPK) approaches in to build and validate mechanistic in vitro-in vivo correlations (IVIVCs) for long-acting injectable (LAI) technologies through a joint proposal with the University of Connecticut’s School of Pharmac...

November 13, 2024 1 EN
 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus to Participate in the Stephens Annual Investment Conf...

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that Shawn O’Connor, chief executive officer, will participate in a fireside chat at the Stephens Annual Investment Conference in Nashville, TN, on Wednesday, November 20, 2024, at 12:00 p.m. Eastern Time. In addition, Mr. O’Connor will host one-on-one meetings with investors throughout the day. The live audio webcast of Mr. O’Connor’s...

November 6, 2024 1 EN
 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus and Partners Awarded New FDA Grant to Validate In Vit...

LANCASTER, Calif.--(BUSINESS WIRE)-- (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced a newly funded grant from the U.S. Food and Drug Administration (FDA), secured in partnership with the University of Strathclyde and InnoGI Technologies. The project is expected to improve the understanding of amorphous solid dispersion (ASD) formulations in different conditions and predict the impact of food and pH-dependent drug-drug interactions (DDIs) th...

October 30, 2024 1 EN
 PRESS RELEASE
Free
SLP Simulations Plu...

Simulations Plus Reports Fourth Quarter and Fiscal 2024 Financial Resu...

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024. Fourth Quarter 2024 Financial Highlights (compared to fourth quarter 2023) Total revenue increased 19% to $18.7 million Software revenue increased 6% to $9.9 million, representing 53% of total revenue Services revenue increased 39% to $8.8 million, re...

October 23, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch